Active Bacterial Core Surveillance (ABCs) Report
Emerging Infections Program Network
Neisseria meningitidis, 1998

CDC
CENTERS FOR DISEASE CONTROL AND PREVENTION

ABCs Areas

California (3 county San Francisco Bay area); Connecticut; Georgia; Maryland; Minnesota; New York (5 county Rochester area); Oregon; Tennessee (5 urban counties)

ABCs Population

The surveillance areas represent 30,410,810 persons.
Source: U.S. Bureau of the Census, 1998

ABCs Case Definition

Invasive meningococcal disease: isolation of *Neisseria meningitidis* from normally sterile site in a resident of a surveillance area in 1998.

ABCs Methodology

Project personnel communicated at least monthly with contacts in all microbiology laboratories serving acute care hospitals in their area to identify cases. Standardized case report forms that include information on demographic characteristics, clinical syndrome, and outcome of illness were completed for each identified case. Molecular subtyping was done on meningococcal isolates at CDC. Regular laboratory audits assess completeness of active surveillance and detect additional cases.

All rates of invasive meningococcal disease were calculated using U.S. Bureau of the Census postcensal population estimates for 1998.

Oregon has been experiencing a meningococcal outbreak with a site specific rate more than double the other surveillance sites. Thus, for national projections, race- and age-specific rates of disease were applied from the aggregate surveillance areas, excluding Oregon, to the race- and age-specific distribution of the 1998 U. S. population, excluding Oregon, and then the number of cases or deaths from Oregon were added.

Cases with unknown race were distributed by area based on reported race distribution for known cases within the eight age categories.

Reported ABCs Profiles

Race	No. (Rate*)	
White	232	(1.0)
Black	73	(1.4)
Other	12	(0.8)
Total	317	(1.0)

Unknown race (n=29) distributed among knowns

*Cases per 100,000 population for ABCs areas.

Syndrome	Cases No. (%*)		Deaths No. (Rate[†])	
Meningitis	144	(45.4)	17	(11.8)
Bacteremia w/o	139	(43.8)	20	(14.4)

*Percent of cases.   [†]Deaths per 100 cases.

Serogroups

Age (years	B No. (Rate*)		C No. (Rate)		Y No. (Rate)		Other No. (Rate)	
<1	10	(2.4)	3	(0.7)	10	(2.4)	7	(1.7)
1	4	(1.0)	2	(0.5)	6	(1.4)	5	(1.2)
2-4	11	(0.9)	13	(1.0)	4	(0.3)	2	(0.2)
5-17	24	(0.4)	26	(0.5)	17	(0.3)	11	(0.2)
18-34	17	(0.2)	16	(0.2)	16	(0.2)	8	(0.1)
35-49	11	(0.1)	4	(0.1)	10	(0.1)	5	(0.1)
50-64	2	(0.05)	5	(0.1)	15	(0.3)	7	(0.2)
≥65	6	(0.2)	5	(0.1)	25	(0.7)	10	(0.3)
Total	85	(0.3)	74	(0.2)	103	(0.3)	55	(0.2)

* Cases per 100,000 population for ABCs areas

Serogroup B Isolates

Serosubtypes	No. (%)		Serotypes: Serosubtype	No. (%)	
P1.7,16	39	(50)	15:P1.7,16	33	(42)
P1.7	8	(10)	15:P1.7	6	(8)
P.1.23,14	5	(6)	4,7:P1.7,16	6	(8)
P1.7,1	4	(5)	07:NT	3	(4)
P1.5,2	3	(4)	4,7:P1.23,14	3	(4)

Of 39 isolates from Oregon, 34 (87%) were P1.7,16

Of 39 isolates from Oregon, 28 (72%) were 15:P1.7,16

National Projection for Invasive Disease:

Cases: 2,500 (0.9/100,000)
Deaths: 400 (0.1/100,000)

Healthy People 2010 Update:

Objective: Reduce the incidence of invasive meningococcal disease to 0.9 per 100,000 population.

2010 Objective	1998 Rate*
0.9/100,000	0.99

*Cases per 100,000 U.S. population.

Source: NETSS

For more information, visit our web site at:

http://www.cdc.gov/ncidod/dbmd/abcs